Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in Participants With Obsessive-Compulsive Disorder (OCD)

ClinicalTrials.gov ID: NCT01674361

Public ClinicalTrials.gov record NCT01674361. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 8:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Combination With Selective Serotonin Reuptake Inhibitors in Patients With Obsessive Compulsive Disorder

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This multicenter, randomized, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of bitopertin in combination with SSRI in participants with obsessive-compulsive disorder. Participants will be randomized to receive either bitopertin 30 milligrams (mg) or bitopertin 10 mg or placebo orally daily in addition to their background therapy with an SSRI. Participants will be allocated to one of two strata. Participants in Stratum 1 will start study drug on Day 1. Participants in Stratum 2 will receive placebo from Day 1 (placebo lead-in) and will then start study drug at the Week 2 visit. Participants in both strata will receive the study drug in addition to their background therapy with an SSRI until Week 16.

Study identification

NCT ID
NCT01674361
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
99 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 30, 2012
Primary completion
Apr 29, 2015
Completion
Apr 29, 2015
Last update posted
Aug 1, 2017

2012 – 2015

United States locations

U.S. sites
27
U.S. states
19
U.S. cities
25
Facility City State ZIP Site status
Excell Research Oceanside California 92056
Stanford University School of Medicine Stanford California 94305
Yale University School of Medicine; Neuroscience Research Training Program New Haven Connecticut 06519
Compass Research North, LLC Leesburg Florida 34748
Medical Research Group of Central Florida Orange City Florida 3273
University of South Florida St. Petersburg Florida 33701
University of South Florida Tampa Florida 33613-4706
iResearch Atlanta Decatur Georgia 30030
Carman Research Smyrna Georgia 30080
Uni of Chicago; Centre For Advanced Medicine Chicago Illinois 60637
Louisiana Research Associates New Orleans Louisiana 70114
Massachusetts General Hospital - East Boston Massachusetts 02114
Boston Clinical Trials Boston Massachusetts 02131
Ambulatory Research Center (ARC), Department of Psychiatry Minneapolis Minnesota 55454
Precise Research Centers Flowood Mississippi 39232
St Louis Clinical Trials St Louis Missouri 63141
Mount Sinai School of Medicine; Department of Psychiatry New York New York 10029
Medical Research Network - New York New York New York 10128
Finger Lakes Clinical Research Rochester New York 14618
North Star Research Middleburg Heights Ohio 44130
Ips Research Company Oklahoma City Oklahoma 73103
Keystone Clinical Studies, LLC Norristown Pennsylvania 19403
Butler Hospital - Department of Psychiatry and Human Behavior Providence Rhode Island 02906
Clinical Neuroscience Solutions,Inc Memphis Tennessee 38119
FutureSearch Trials, LP Austin Texas 78731
Eastside Therapeutic Resource Kirkland Washington 98033
Dean Foundation Middleton Wisconsin 53562

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01674361, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 1, 2017 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01674361 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →